Completed PHASE1 INTERVENTIONAL 3-arm NCT00856752

Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine

A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part A: Interaction With Rifampicin and Cyclosporine

Sponsor: Norgine

Conditions Pharmacokinetics

Interventions NRL972

Updated 4 times since 2017 Last updated: Mar 5, 2009 Started: Jun 30, 2006 Primary completion: Jul 31, 2006 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pharmacokinetics and is currently completed. Norgine leads this study, which shows 4 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Norgine

Data source: Norgine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sofia, Bulgaria